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I
diopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the histologic appearance in a lung biopsy of usual interstitial pneumonia (UIP). 1 The etiology is unknown. Examination of affected pulmonary tissue reveals inflammatory infiltrates, composed principally of T lymphocytes and macrophages, with variable numbers of mast cells, neutrophils, and eosinophils and distinct B-lymphocyte aggregates. 2, 3 Advances in immune reactions have shown that an imbalance between T-helper type 1 (Th1) cells and T-helper type 2 (Th2) cells plays a pivotal role in the For editorial comment see page 1187 inflammatory response of various diseases. 4 Studies have revealed a predominance of the Th2 cytokine pattern in the inflammatory response of IPF. The Th2-like pattern of immune response predominated in the infiltrating interstitial inflammatory cells and hyperplastic type II epithelial cells of patients with IPF. 5, 6 A significantly higher level of interleukin (IL)-4 was observed in the co-cultures of T cells with autologous alveolar macrophages from patients with IPF. 7 These findings suggest that the Th2-mediated inflammatory response may be involved in the inflammatory and fibroproliferative process of IPF.
It is now well established that there is a strong link between the overexpression of proinflammatory cytokines, including tumor necrosis factor (TNF)-␣ and IL-1␤, in the lower respiratory tract and the development of pulmonary fibrosis. 8 -11 IL-1␤ and TNF-␣ had a stimulatory effect on fibroblasts to synthesize collagen. 8 In patients with IPF, TNF-␣ and IL-1␤ expression by alveolar and interstitial macrophages and type II epithelial cells have been reported to increase. 9 -11 The ST2 gene, also designated T1, Fit-1, and DER4, was originally detected as one of the primary response genes at the initial stage of cell proliferation in fibroblasts. [12] [13] [14] [15] [16] It is classified in the IL-1 receptor family due to the proximity of its locus to IL-1r1 in both mouse and human chromosomes. [17] [18] [19] [20] Studies [21] [22] [23] [24] have shown that ST2 gene products are predominantly expressed in Th2 cells but not in Th1 cells, suggesting that they may play novel roles in the immunologic response in addition to their roles in cell proliferation. We previously constructed an enzyme-linked immunosorbent assay system to quantify the human ST2 protein (ST2) in sera, and revealed that patients with atopic asthma exhibit significantly higher levels of serum soluble ST2 than healthy control subjects. 25, 26 Furthermore, ST2 could be expressed significantly when induced by proinflammatory cytokines such as TNF-␣ and IL-1␤. 27 These findings suggest that the ST2 gene may have been related to Th2 immune response as well as to inflammatory response.
We therefore hypothesized that the expression of ST2 may be up-regulated, reflecting an inflammatory response induced by Th2 cytokine and proinflammatory cytokine in IPF. To test this hypothesis, we analyzed the serum levels of ST2 in patients with IPF and evaluated the relationship of ST2 to the pathogenesis of IPF.
Materials and Methods

Subjects
We conducted a retrospective study of 49 patients with IPF who were admitted to Jichi Medical School Hospital. The median age at the time of hospital admission was 66.9 years (range, 44 to 84 years). The diagnosis of IPF was based on an international consensus statement (ICS). 1 The diagnoses of IPF were obtained by video-assisted thoracoscopic surgery (VATS) in 20 patients, and by autopsy in 4 patients ( Table 1 ). In the remaining 25 patients, IPF was diagnosed clinically on the basis of a typical finding of IPF on CT scans of the chest and pulmonary function testing as stated in the ICS. Exclusion criteria consisted of other known causes of interstitial lung disease such as drug toxicities, environmental exposures, and collagen vascular diseases. Fortynine patients with IPF were admitted to our hospital 64 times: 36 patients were admitted once, 11 patients were admitted twice, and 2 patients were admitted three times. The reasons for hospital admission were further examination (n ϭ 27), acute exacerbation (n ϭ 14), bacterial pneumonia (n ϭ 11), induction of home oxygen therapy (HOT) [n ϭ 9], heart failure (n ϭ 2), and pneumothorax (n ϭ 1) [ Table 1 ]. We analyzed the serum ST2 levels in 64 samples obtained at the time of the hospital admission. An acute exacerbation of IPF is characterized by the histopathologic pattern of diffuse alveolar damage (DAD) with 28 -30 An acute exacerbation in patients with IPF was defined as follows: for the accelerated phase of IPF, exacerbation of dyspnea within 1 month, new diffuse pulmonary opacities on chest radiography, a decrease in Pao 2 of Ͼ 10 mm Hg, and an absence of infection or heart failure. 29, 30 We defined stable IPF as IPF without acute exacerbation. Among the 64 events for which these patients with IPF were admitted to the hospital, 50 of the events occurred during stable IPF and 14 events occurred during acute exacerbation of IPF (Table 1) . Serum samples in our study were obtained during early phase of acute exacerbation. In turing cases of acute exacerbation of IPF, a histopathologic pattern of DAD with UIP was confirmed at autopsy in four patients. Severity of lung injury was assessed semiquantitatively according to the method described by Murray and coworkers. 31 The lung injury scores of the 14 patients with an acute exacerbation of IPF fell into the category of moderate-to-severe lung injury (mean lung injury score Ϯ SD, 2.6 Ϯ 0.8; range, 1.5 to 4.0), and all of these patients died in the hospital despite steroid therapy (mean survival time after hospital admission Ϯ SD, 79 Ϯ 99 days; range, 5 to 274 days). Three patients with stable IPF had bronchial asthma, and two patients with an acute exacerbation of IPF received steroid therapy before hospital admission ( Table 1) . As a control group, 200 healthy control volunteers were also included in this study.
Pulmonary Function Tests and Blood Gas Analyses
In 50 stable IPF events, pulmonary function tests were performed for 36 of the events that occurred in patients with IPF admitted to the hospital for further examination (n ϭ 27) or for the induction of HOT (n ϭ 9). Pulmonary function tests included FEV 1 , the ratio of FEV 1 to forced expiratory vital capacity (FEV 1% ), vital capacity (VC), the percentage of predicted VC (%VC), and the percentage of predicted carbon monoxide diffusing capacity (%Dlco).
In all 64 events, blood gas samples were obtained at hospital admission. Blood gas samples were obtained at room air in 43 events, during the inhalation of oxygen in 19 events, and during controlled ventilation in 2 events. Since we could not determine the fraction of inspired oxygen (Fio 2 ) in 19 events, we evaluated the Pao 2 and Paco 2 at room air in 43 events, and the ratio of the Paco 2 to Fio 2 in 45 events.
Blood Samples
Sixty-four peripheral venous blood samples with and without ethylenediaminetetra-acetic acid were obtained at the time of the hospital admission. After centrifugation at 3,000g for 10 min at 4°C, the serum was frozen and stored at Ϫ 80°C until assayed.
Measurement of ST2 and Several Variables
Peripheral blood samples were measured for a full blood count. The serum samples were analyzed for ST2, lactate dehydrogenase (LDH), C-reactive protein (CRP), and total IgE. ST2 concentration was determined by sandwich enzyme-linked immunosorbent assay as previously described. 25, 26 In brief, to calibrate the purified recombinant human ST2 assay of various concentrations in phosphate-buffered saline solution ϩ 0.1% (weight/volume) bovine serum antigen, sera from healthy volunteers and patients were added to a 96-well plate coated with FB9, an antihuman ST2 monoclonal antibody. After 1 h, the plate was washed three times with phosphate-buffered saline solution ϩ 0.05% (weight/volume) Tween 20. Then, 50 L of 500 ng/mL of biotinylated 2A5 monoclonal antibody was added to each well and reacted for 1 h. After being washed three times, streptavidine-horseradish peroxidase conjugate was added and allowed to react for 30 min. After being washed five times, the plate was reacted with 100 L of 10 mmol/L o-phenylenediamine-0.01% (volume/volume) H 2 O 2 in 50 mmol/L sodium acetate buffer (pH 5.0) for 20 min. The optical density at 450 nm was measured. All of the samples were assayed in duplicate.
Statistical Analysis
Data were expressed as mean Ϯ SEM. Differences between two variables were assessed with the Mann-Whitney U test. Multiple comparison was carried out by the Fisher protected least-significant differences method followed by the post hoc test. Positive quantitative differences between groups were tested by 2 test or the Fisher exact probability test. Analysis of correlation was done with the Pearson coefficient of correlation. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were calculated for the serum ST2 level to analyze the optimal criteria for discriminating cases between acute exacerbation and stable state of IPF; p Ͻ 0.05 was considered statistically significant.
Results
Serum Concentration of ST2 in Patients With IPF
The serum ST2 levels in the 64 events of patients with IPF were elevated compared to those of healthy control subjects (median values of patients with IPF vs healthy control subjects, 0.94 ng/mL vs 0.42 ng/mL, respectively), and there was a significant difference in serum ST2 levels between the two groups (p Ͻ 0.0001, Fig 1) . We classified 64 subjects into two groups: the 50 subjects whose events occurred in stable IPF, and the 14 subjects whose events occurred on acute exacerbation of IPF. Although the serum levels of ST2 in stable IPF statistically did not differ from those in healthy control subjects, the serum levels of ST2 in acute exacerbation of IPF were significantly higher than those in stable IPF (p Ͻ 0.0001, acute exacerbation of IPF vs stable IPF or healthy control subjects, 2.76 Ϯ 0.56 ng/mL vs 0.44 Ϯ 0.07 ng/mL or 0.42 Ϯ 0.03 ng/mL, respectively, as shown in Fig 2) . In 11 events of bacterial pneumonia with stable IPF, the serum ST2 levels were not elevated (data not shown).
Positive Rate of Serum ST2
The cutoff values of serum ST2 were set at 1.33 ng/mL on the basis of the 95% specificity level for the healthy control group. The positive rate of serum ST2 in acute exacerbation of IPF was 71.4% and was significantly higher than that in stable IPF or healthy control subjects (Fig 3) . The serum levels of ST2 were below the cutoff values in 92% of the patients with stable IPF.
Evolution of Serum ST2
In six patients with IPF, serum samples at two points, before acute exacerbation and in acute exac-erbation, could be obtained and compared. The ST2 levels in these six patients did not increase before acute exacerbation. The levels of serum ST2 on acute exacerbation were, however, significantly elevated in comparison with those before acute exacerbation of IPF in each case (p Ͻ 0.05; before acute exacerbation vs on acute exacerbation, 0.29 Ϯ 0.09 ng/mL vs 1.92 Ϯ 0.67 ng/mL, respectively; Fig 4) .
Correlation of Serum ST2 Levels to Several Variables
Various clinical parameters of the patients with IPF are shown in Table 2 . Physiologic parameters were consistent with a restrictive disorder (reduced %VC). In addition, gas exchange abnormalities were evident with a reduction in the %Dlco, Pao 2 , and Pao 2 /Fio 2 . Although the serum LDH and CRP were increased, the total serum IgE, WBC count, and eosinophils were not elevated. Factors associated with the serum ST2 levels in patients with IPF were analyzed using the Pearson correlation coefficient test (Table 3 
Serum ST2 Levels in the Diagnosis of Acute Exacerbation of IPF
We evaluated serum ST2 as a marker for acute exacerbation of IPF. The cutoff values of serum ST2 were set at 1.33 ng/mL on the basis of the 95% specificity level for the healthy control group. Cutoff levels of other markers were set at 8,000/L for WBC count, 0.5 mg/dL for CRP, and 410 IU/L for LDH. Using these cutoff levels, the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy in the diagnosis of acute exacerbation of IPF for each marker are shown in Table 4 . Overall, measurement of serum ST2 levels in the diagnosis of acute exacerbation of IPF gave the highest diagnostic accuracy.
Discussion
Although little is known about the pathogenesis of IPF, it is hypothesized that several interacting factors that modify the fibrotic response include the genetic background of the patient, environmental inflammatory triggers, and the predominant inflammatory phenotype (Th1 or Th2). 32 The inflammatory response may modulate tissue injury, fibrosis, or both during the evolution of IPF. It has been reported that the inflammatory response in IPF is thought to be associated with proinflammatory cytokines and Th2 immune response. [5] [6] [7] [8] [9] [10] [11] Reports 21-23,27 have demonstrated that ST2 gene products are predominantly expressed in Th2 cells, and that their expression is also significantly induced by proinflammatory cytokines; therefore, we hypothesized that ST2 gene expression may be up-regulated, reflecting an inflammatory response induced by Th2 cytokine or proinflammatory cytokine in IPF. The results of the present study demonstrated that the serum ST2 levels in patients with stable IPF did not differ from those in healthy control subjects, while the serum levels of ST2 in patients with acute exacerbation of IPF were significantly elevated. Furthermore, the serum level of ST2 was statistically correlated with LDH and CRP. These findings suggest that the serum ST2 level may reflect progress in the inflammatory process in the lung in IPF. Most patients with IPF show a slowly progressive deterioration characterized by progressive parenchymal lung injury and fibrosis leading to restrictive lung function, decreased diffusing capacity and, ultimately, cor pulmonale. However, Kondoh et al 30 reported that an accelerated phase occurs at some point during the chronic course of the disease. Furthermore, open-lung biopsy performed within 2 weeks after the exacerbation confirmed an acute DAD pattern together with a chronic interstitial pneumonia of the UIP type. 30 Although it remains uncertain what causes acute exacerbation, the pathologic findings of lung autopsy specimens with respect to acute exacerbation of IPF demonstrated that IL-1␤ and TNF-␣ were strongly positive in the Figure 3 . Positive rate of serum ST2. The cutoff values are set at 1.33 ng/mL on the basis of the 95% specificity level for the healthy control group. The positive rate in acute exacerbation of IPF is significantly higher than that in stable IPF (p Ͻ 0.0001, acute exacerbation of IPF vs stable IPF; acute exacerbation of IPF, 10 of 14 ϭ 71.4%; stable IPF, 4 of 50 ϭ 8.0%, respectively). There was no significant difference between stable IPF and healthy control subjects. NS ϭ not significant. alveolar macrophages and proliferating type II pneumocytes. 28 It has been reported that both IL-1␤ and TNF-␣ lead to acute/subacute and chronic inflammation that evolve into pulmonary fibrosis, and that the transient overexpression of IL-1␤ or TNF-␣ has a great effect in promoting fibrosis. 33, 34 These findings suggest that IL-1␤ and TNF-␣ may be involved in the pathogenesis of the acute exacerbation of IPF; however, an in vitro study 27 demonstrated that the expression of ST2 was enhanced by proinflammatory cytokines, such as IL-1␣, IL-1␤, and TNF-␣. The results of the present study demonstrated that the levels of serum ST2 were significantly elevated on acute exacerbation of IPF; therefore, proinflammatory cytokines such as IL-1␤ and TNF-␣ may enhance the expression of ST2 on acute exacerbation of IPF. The elevated levels of soluble ST2 protein may be related to the inflammatory process of the accelerated phase of IPF, and reflect the severity of lung inflammation.
The inflammatory response in pulmonary fibrosis has been thought to be closely associated with a Th2 immune response. Interferon (IFN)-␥ inhibits fibroblast proliferation and the production of collagen and other noncollagenous extracellular matrix proteins by these cells, while IL-4 promotes it. [35] [36] [37] In vivo studies 38,39 using a bleomycin-induced pulmonary fibrosis model have also supported this concept by demonstrating that IL-4 messenger RNA expression is up-regulated in lung fibrosis lesions and that IL-12 attenuates pulmonary fibrosis via the modulation of IFN-␥ production. Furthermore, in the clinical study, IFN-␥ treatment of patients with IPF was seen to improve pulmonary function and gas exchange. 40 These findings suggest that the persistent imbalance in the expression of Th1 and Th2 cytokines in the lung may be one of the important underlying factors in the progression of pulmonary fibrosis. There have been several reports 25, 26, 41 demonstrating that serum ST2 protein increases in Th2-mediated disease, such as acute eosinophilic pneumonia and bronchial asthma; therefore, if Th2-mediated inflammation is related to the fibroproliferative process, we expect that the serum ST2 level may increase in IPF, reflecting the activity of IPF.
The results of the present study, however, demonstrated that the serum levels of ST2 were not elevated in stable IPF; however, the possibility that ST2 expression may be implicated in the fibroproliferative process cannot be denied, because serum levels of ST2 may not reflect the local expression of ST2 in the lung tissue. Previous reports 5, 6 regarding Th2 cytokine expression in IPF have demonstrated that Th2 cytokines, such as IL-4 or IL-5, are overexpressed in the lung tissue, but not in the serum. Further analysis is required to investigate the correlation of the local expression of ST2 and Th2 cytokines in the IPF lung. Although the origin of the elevated serum ST2 in patients with IPF is unknown, several investigators have reported on the cellular source of ST2. Li et al 20 showed that the messenger RNA of human ST2 was highly expressed in the tissues of the lung, kidney, placenta, and stomach. Kumar et al 27 showed that the messenger RNA of ST2 was expressed in mast cells, fibroblasts, and vascular endothelial cells. We also observed ST2 messenger RNA expression in human bronchial epithelial cells, type II pneumocytes, alveolar macrophages, pulmonary smoothmuscle cells, pulmonary artery endothelial cells, and lung fibroblasts. 42 Parenchymal inflammation in IPF involves T lymphocytes, macrophages, mast cells, neutrophils, eosinophils, hyperplastic type II epithelial cells, fibroblast proliferation, and distinct Blymphocyte aggregates. 2, 3 These findings suggest that ST2 in acute exacerbation of IPF may be produced by lung structural cells or infiltrating interstitial inflammatory cells. Further analysis such as in situ hybridization or immunohistochemistry is needed to determine which cells produce ST2 protein in IPF.
To evaluate the clinical role of the serum ST2, we analyzed the correlation between ST2 and various clinical parameters. Interestingly, the present study demonstrated that the serum levels of ST2 inversely correlated with Pao 2 , Pao 2 /Fio 2 , and %VC. Furthermore, the serum levels of ST2 statistically correlated with those of LDH, which could reflect the cellular destruction of lung cells in diffuse interstitial pneumonitis. 43 These findings suggest that soluble ST2 in sera may increase, possibly reflecting the severity of respiratory insufficiency and restrictive pulmonary dysfunction caused by progressing fibrosis in the IPF lung. Moreover, our results demonstrated that measurement of serum ST2 levels in the diagnosis of acute exacerbation of IPF gave the higher diagnostic accuracy than other markers, suggesting that elevated serum ST2 levels might predict an acute exacerbation of IPF. However, given the small number of patients, a larger confirmatory study is necessary to ascertain how applicable these results are to patients with IPF in general.
Although the biological function of elevated ST2 in the patients with IPF is still uncertain, there have been several reports suggesting the function of soluble ST2 protein in murine models. In murine asthma models, the administration of recombinant ST2 fusion protein or IV soluble ST2 gene transfer attenuates eosinophilic inflammation of the airway and suppresses IL-4 and IL-5 production, and these data suggest that soluble forms of ST2 can inhibit the interaction of membrane-bound ST2 by competing with its putative ligand, resulting in down-regulation of the Th2 effector function. 23, 44, 45 Furthermore, Sweet et al 46 showed that the administration of a recombinant ST2 fusion protein suppresses TNF-␣ production and results in a significantly enhanced survival rate in murine lipopolysaccharide-induced shock models. These findings suggest that soluble forms of ST2 may have the capability to inhibit the production of proinflammatory cytokines and Th2 cytokines. Although protective roles of ST2 have been reported in animal models, it is difficult to extrapolate these results of animal study to human pathologic conditions, such as IPF; however, we can speculate that the elevation in endogenous ST2 in the lung was too late or too low to prevent acute lung injury or pulmonary fibrosis. An experimental study utilizing a model of bleomycin-induced pulmonary fibrosis is underway to determine the role and function of ST2 gene products in pulmonary fibrosis.
Conclusion
Our results show that the serum ST2 levels are significantly elevated in patients with acute exacerbation of IPF, and that these levels correlate with the serum levels of LDH and CRP, and inversely correlate with Pao 2 , Pao 2 /Fio 2 , and %VC. These results suggest that ST2 in the serum may increase, possibly reflecting the development of the inflammatory process and the Th2 immune response in the IPF lung. The regulation of ST2 expression, interaction with other cytokines, and local expression of ST2 in the lung should be further analyzed.
